Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Conavi Medical ( (TSE:CNVI) ).
Conavi Medical has secured an agreement with the Province of Ontario under the Life Sciences Scale-Up Fund, which will provide up to $2.5 million CAD to aid in the commercial launch of its next-generation Novasight Hybrid system. This funding will support Conavi’s efforts to enhance its cardiovascular imaging technology, potentially positioning the company as a leader in the field and reinforcing Ontario’s status as a hub for life science innovation. The Novasight Hybrid system’s dual-modality approach aims to improve the precision of cardiovascular diagnoses and treatments, benefiting both the company and the broader medical community.
The most recent analyst rating on (TSE:CNVI) stock is a Buy with a C$1.00 price target. To see the full list of analyst forecasts on Conavi Medical stock, see the TSE:CNVI Stock Forecast page.
More about Conavi Medical
Conavi Medical is a commercial-stage medical device company that specializes in designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures. The company’s patented Novasight Hybrid System uniquely integrates intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, facilitating comprehensive imaging of coronary arteries. The system has regulatory clearance in the U.S., Canada, China, and Japan.
Average Trading Volume: 27,382
Technical Sentiment Signal: Sell
Current Market Cap: C$31.53M
For detailed information about CNVI stock, go to TipRanks’ Stock Analysis page.